Myocardial Ribonuclease Activity in Heart Failure

  • P. J. O’Brien
  • H. Shen
  • J. K. Gwathmey
Part of the Developments in Cardiovascular Medicine book series (DICM, volume 167)

Summary

We recently observed that degradation of RNA isolated from myocardium of dogs with heart failure (HF) was abnormally increased. Accordingly, we tested the hypothesis that, compared with healthy myocardium, ribonuclease (RNase) activity was increased in HF occurring due to various etiologies and in various species, including idiopathic and ischemic cardiomyopathies in humans, idiopathic dilated cardiomyopathy in dogs, rapid ventricular pacing in dogs, furazolidone toxicosis in turkeys, and hypothermia in chickens. Activity was determined using a fluorometric, kinetic assay for homogenized myocardium diluted 83-fold with physiologic saline containing 10mg/ml ethidium bromide and yeast RNA as a substrate. The mean activity of myocardial extracts was increased in 6 failing compared with 7 nonfailing human hearts (34.6 ± 6.9 and 62.3 ± 19.1 units/sec), 14 failing compared with 11 nonfailing dog hearts (15.0 ±4.1 and 38.3 ± 6.4 units/esc), 14 failing compared with 13 nonfailing turkey hearts (30.1 ±4.7 and 39.3 ± 4.4units/sec), and 9 failing compared with 5 nonfailing chicken hearts (17.0 ± 3.5 and 25.7 ± 5.4units/sec) In all P < 0.0001). These data indicate that in HF produced from various causes in various species, there is increased myocardial RNase activity. We conclude that the increased RNA degradation that occurs in HF can be attributed to increased RNase activity.

It is generally accepted that there is decreased mRNA content for various key proteins involved in metabolism and Calcium (Ca2+) homeostasis [1,2]. However, it has not been determined to what extent the decrease is attributable to decreased RNA stability compared with decreased gene expression. In a recent study of myocardial mRNA content in dogs with end-stage heart failure (HF) due to idiopathic dilated cardiomyopathy (IDCM) or rapid ventricular pacing (RVP), we observed abnormally increased degradation of the RNA and abnormally increased total and ribosomal RNA [3]. We hypothesized that this was attributable to increased myocardial RNase activity and that it was a consistent feature of HF, regardless of etiology or the species of animal affected.

We used a fluorescent kinetic assay [4] to determine RNase activity in supernatants of centrifuged myocardial homogenates. Ethidium bromide (EtBr) was used as the RNA dye because it forms a fluorescent complex with nonhydrolyzed RNA but fails to fluoresce in the presence of hydrolyzed RNA. Thus RNase activity can be determined by observing the change in fluorescence over time as a standard amount of RNA is hydrolyzed by the myocardial extract.

We determined RNase activity in nonfailing myocardium from people, dogs, turkey, and chickens, and in myocardium from people with IDCM or ischemic cardiomyopathy (ISCM), from dogs with HF due to IDCM or RVP, from turkeys with furazolidone cardiomyopathy, and from broiler chickens with HF produced by hypothermia and a high-protein diet.

Keywords

Dioxide Bromide Turkey Cardiomyopathy Cardiol 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Arai M, Matsui H, Periasamy M. Sarcoplasmic reticulum gene expression in cardiac hypertrophy and heart failure. Circ Res 74:555–564, 1994.PubMedCrossRefGoogle Scholar
  2. 2.
    Takahashi T, Allen PD, Izumo S. Expression of A-, B-, and C-type natriuretic peptide genes in failing and developing human ventricles. Correlation with expression of the Ca2+-ATPase gene. Circ Res 71:9–17, 1992.Google Scholar
  3. 3.
    O’ Brien PJ, Duke AL, Shen Hua, Shohet RV. Myocardial mRNA content and stability and enzyme activities of Ca-cycling and aerobic metabolism in idiopathic dilated cardiomyopathy of dogs. Mol Cell Biochem 42:139–150, 1995.CrossRefGoogle Scholar
  4. 4.
    Kamm RC, Smith AG, Lyons H. A fluorometric method for assay of RNase activity. Anal Biochem 37:333–336, 1970.PubMedCrossRefGoogle Scholar
  5. 5.
    O’ Brien PJ, Ianuzzo CD, Moe GW, Howard RJ, Stopps TP, Armstrong PW. Rapid ventricular pacing in the dog: Biochemical and physiological studies of heart failure. Can J Physiol Pharmacol 68:34–39, 1990.PubMedCrossRefGoogle Scholar
  6. 6.
    O’ Brien PJ, O’ Grady M, McCutcheon LJ, Nowack L, Horn RD, Mirsalimi SM, Julian RJ, Moe GW, Armstrong PW. Myocardial myoglobin deficiency in various animal models of congestive heart failure. J Mol Cell Cardiol 24:721–730, 1992.PubMedCrossRefGoogle Scholar
  7. 7.
    O’Brien PJ, Shen H, Weiler JE, Mirsalimi SM, Julian RJ. Myocardial calcium cycling defect in furazolidone cardiomyopathy. Can J Physiol Pharmacol 69:1833–1840, 1991.PubMedCrossRefGoogle Scholar
  8. 8.
    Glass MG, Fuleihan F, Liao R, Lincoff M, Chapados R, Hamlin R, Apstein CS, Allen PD, Ingwall JS, Hajjar RJ, Cory CR, O’ Brien PJ, Gwathmey JK. Differences in cardioprotective efficacy of adrenergic receptor antagonists and Ca2+ channel antagonists in an animal model of dilated cardiomyopathy: Effects on gross morphology, global cardiac function, and twitch force. Circ Res 73:1077–1089, 1993.PubMedCrossRefGoogle Scholar
  9. 9.
    Julian RJ. Are we growing them too fast? Ascites in meat-type chickens. Highlights 10:27–30, 1987.Google Scholar
  10. 10.
    McCutcheon LJ, Cory CR, Nowack L, Shen H, Mirsalimi M, Lahucky R, Kovac L, O’ Grady M, Home MR, O’ Brien PJ. Respiratory chain defect of myocardial mitochondria in idiopathic cardiomyopathy of Doberman pinscher dogs. Can J Physiol Pharmacol 70: 1529–1533, 1992.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1995

Authors and Affiliations

  • P. J. O’Brien
  • H. Shen
  • J. K. Gwathmey

There are no affiliations available

Personalised recommendations